Clene Inc. (CLNN) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Clene secured a critical debt restructuring with a second amendment to convertible notes, extending the maturity date to August 13, 2027 and deferring $1 million monthly payments that were set to begin September 2026, providing near-term liquidity relief.
The company faces significant related-party concentration risk, with all three note holders having material connections to Clene's operations: Kensington controlled by board member Alison Mosca, 4Life holding supply agreements with Clene's subsidiary, and La Scala controlled by 4Life's co-founder who sits on the subsidiary's board.
The deferral of debt payments indicates potential liquidity constraints, as the full principal and accrued interest balance is now due by August 2027, creating a material refinancing or repayment obligation within approximately 15 months.
Q1 2026 financial results were announced alongside this debt restructuring, suggesting the company may be facing operational or financial headwinds that necessitated the amended payment terms.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-05

Clene Inc. is raising $7 million gross proceeds ($6.4 million net) through a public offering of 1 million shares at $7.00 per share, indicating potential cash needs for clinical development and commercialization activities.
The company plans to deploy capital toward NDA preparation and filing for its lead drug candidate CNM-Au8, expanded access protocols, Phase 3 clinical trials, and manufacturing expansion, suggesting progress in advancing its pipeline toward commercialization.
A 60-day lock-up agreement restricts company insiders and directors from selling shares post-offering, which is standard practice but limits insider liquidity and demonstrates underwriter confidence in the offering.
The offering is priced at $7.00 per share through an S-3 registration statement, with Canaccord Genuity as sole bookrunner and the company also maintaining an equity distribution agreement with the same underwriter for future capital raises.

Filed: 2026-05-04

FDA confirmed that CNM-Au8's neurofilament light (NfL) biomarker data may support an accelerated approval NDA pathway for ALS treatment, with the agency indicating NfL could serve as a reasonably likely surrogate endpoint—a significant regulatory validation that de-risks the approval process.
Company plans to submit the NDA in Q3 2026 and initiate a Phase 3 confirmatory trial in Q1 2027, demonstrating a clear timeline for regulatory advancement that could position the company for potential accelerated approval while conducting the standard confirmatory study.
The NDA submission will be supported by multiple data sources including Phase 2 HEALEY ALS Platform Trial, open-label extension showing reduced NfL associated with longer survival, Phase 2 RESCUE-ALS Trial, and an NIH-sponsored Expanded Access Protocol, providing robust clinical and biomarker evidence.
CNM-Au8 has already received Orphan Drug Designation for ALS, which provides regulatory benefits including potential market exclusivity and expedited review, strengthening the commercial viability if approved.

Filed: 2026-03-17

Clene Inc. has secured a $8 million subaward agreement with New York University for the third year of a $45.1 million grant from the National Institutes of Health to support an Expanded Access Program for their CNM-Au8 treatment of amyotrophic lateral sclerosis.
The agreement allows Clene to use its pre-existing background intellectual property without granting any licenses to NYU or the U.S. government, preserving its proprietary technology.
The continued funding from the NIH grant demonstrates the government's support for Clene's efforts to accelerate access to critical therapies for ALS patients.

Filed: 2026-03-12

Clene Inc. reported its full year 2025 financial results, providing investors with an update on the company's recent operational performance.
The company did not provide any forward-looking guidance or commentary on upcoming milestones, limiting insights into its future plans and growth prospects.
Without additional details on key metrics, drivers, or strategic initiatives, the filing lacks substantive information for investors to fully assess Clene's current position and outlook.

Filed: 2026-02-24

Clene Inc. announced a letter to stockholders highlighting upcoming catalysts for its CNM-Au8 product in 2026.
The press release suggests the company is focused on advancing its lead drug candidate and providing updates to investors.
Investors should monitor the progress of CNM-Au8 and any new developments that could impact the company's future performance.

Other reports for Clene Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.